Download PDF
CC BY 4.0 · Glob Med Genet 2022; 09(01): 034-041
DOI: 10.1055/s-0041-1736567
Original Article

Disease Progression and Mutation Pattern in a Large Cohort of LGMD R1/LGMD 2A Patients from India

Valakunja H. Ganaraja‡   *
1   Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Kiran Polavarapu‡   *
1   Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
2   Division of Neurology, Department of Medicine, Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, The Ottawa Hospital, Ottawa, Canada
,
Mainak Bardhan
1   Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Veeramani Preethish-Kumar
1   Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Shingavi Leena
1   Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Ram M. Anjanappa
1   Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
2   Division of Neurology, Department of Medicine, Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, The Ottawa Hospital, Ottawa, Canada
,
Seena Vengalil
1   Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Saraswati Nashi
1   Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Gautham Arunachal
3   Department of Human Genetics, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Swetha Gunasekaran
3   Department of Human Genetics, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Dhaarini Mohan
1   Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Sanita Raju
1   Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Gopikrishnan Unnikrishnan
1   Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Akshata Huddar
1   Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Valasani Ravi-Kiran
1   Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Priya T. Thomas
4   Department of Psychiatric Social Work, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Atchayaram Nalini
1   Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Calpainopathy is caused by mutations in the CAPN3. There is only one clinical and genetic study of CAPN3 from India and none from South India. A total of 72 (male[M]:female [F] = 34:38) genetically confirmed probands from 72 independent families are included in this study. Consanguinity was present in 54.2%. The mean age of onset and duration of symptoms are 13.5 ± 6.4 and 6.3 ± 4.7 years, respectively. Positive family history occurred in 23.3%. The predominant initial symptoms were proximal lower limb weakness (52.1%) and toe walking (20.5%). At presentation, 97.2% had hip girdle weakness, 69.4% had scapular winging, and 58.3% had contractures. Follow-up was available in 76.4%, and 92.7% were ambulant at a mean age of 23.7 ± 7.6 years and duration of 4.5 years, remaining 7.3% became wheelchair-bound at 25.5 ± 5.7 years of age (mean duration = 13.5 ± 4.6), 4.1% were aged more than 40 years (duration range = 5–20). The majority remained ambulant 10 years after disease onset. Next-generation sequencing (NGS) detected 47 unique CAPN3 variants in 72 patients, out of which 19 are novel. Missense variants were most common occurring in 59.7% (homozygous = 29; Compound heterozygous = 14). In the remaining 29 patients (40.3%), at least one suspected loss of function variant was present. Common recurrent variants were c.2051–1G > T and c.2338G > C in 9.7%, c.1343G > A, c.802–9G > A, and c.1319G > A in 6.9% and c.1963delC in 5.5% of population. Large deletions were observed in 4.2%. Exon 10 mutations accounted for 12 patients (16.7%). Our study highlights the efficiency of NGS technology in screening and molecular diagnosis of limb-girdle muscular dystrophy with recessive form (LGMDR1) patients in India.

Keywords

CAPN3 - muscular dystrophy - LGMDR1 - next-generation sequencing

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.


* These two authors contributed equally to this work.


Supplementary Material



Publication History

Received: 07 July 2021

Accepted: 18 September 2021

Article published online:
09 November 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Dinçer P, Leturcq F, Richard I. et al. A biochemical, genetic, and clinical survey of autosomal recessive limb girdle muscular dystrophies in Turkey. Ann Neurol 1997; 42 (02) 222-229
    CrossrefPubMedGoogle Scholar
  • 2 Martinez-Thompson JM, Niu Z, Tracy JA. et al. Autosomal dominant calpainopathy due to heterozygous CAPN3 C.643_663del21. Muscle Nerve 2018; 57 (04) 679-683
    CrossrefPubMedGoogle Scholar
  • 3 Vissing J, Barresi R, Witting N. et al. A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy. Brain 2016; 139 (Pt 8): 2154-2163
    CrossrefPubMedGoogle Scholar
  • 4 Richard I, Broux O, Allamand V. et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995; 81 (01) 27-40
    CrossrefPubMedGoogle Scholar
  • 5 Campbell RL, Davies PL. Structure-function relationships in calpains. Biochem J 2012; 447 (03) 335-351
    CrossrefPubMedGoogle Scholar
  • 6 Sorimachi H, Hata S, Ono Y. Calpain chronicle–an enzyme family under multidisciplinary characterization. Proc Jpn Acad, Ser B, Phys Biol Sci 2011; 87 (06) 287-327
    CrossrefPubMedGoogle Scholar
  • 7 Beckmann JS, Richard I, Hillaire D. et al. A gene for limb-girdle muscular dystrophy maps to chromosome 15 by linkage. C R Acad Sci III 1991; 312 (04) 141-148
    PubMedGoogle Scholar
  • 8 Sorimachi H, Imajoh-Ohmi S, Emori Y. et al. Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and mu-types. Specific expression of the mRNA in skeletal muscle. J Biol Chem 1989; 264 (33) 20106-20111
    CrossrefPubMedGoogle Scholar
  • 9 Kramerova I, Kudryashova E, Tidball JG, Spencer MJ. Null mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitro. Hum Mol Genet 2004; 13 (13) 1373-1388
    CrossrefPubMedGoogle Scholar
  • 10 Partha SK, Ravulapalli R, Allingham JS, Campbell RL, Davies PL. Crystal structure of calpain-3 penta-EF-hand (PEF) domain - a homodimerized PEF family member with calcium bound at the fifth EF-hand. FEBS J 2014; 281 (14) 3138-3149
    CrossrefPubMedGoogle Scholar
  • 11 Chou FL, Angelini C, Daentl D. et al. Calpain III mutation analysis of a heterogeneous limb-girdle muscular dystrophy population. Neurology 1999; 52 (05) 1015-1020
    CrossrefPubMedGoogle Scholar
  • 12 Gómez-Díaz B, Rosas-Vargas H, Roque-Ramírez B. et al. Immunodetection analysis of muscular dystrophies in Mexico. Muscle Nerve 2012; 45 (03) 338-345
    CrossrefPubMedGoogle Scholar
  • 13 Moore SA, Shilling CJ, Westra S. et al. Limb-girdle muscular dystrophy in the United States. J Neuropathol Exp Neurol 2006; 65 (10) 995-1003
    CrossrefPubMedGoogle Scholar
  • 14 Pathak P, Sharma MC, Sarkar C. et al. Limb girdle muscular dystrophy type 2A in India: a study based on semi-quantitative protein analysis, with clinical and histopathological correlation. Neurol India 2010; 58 (04) 549-554
    CrossrefPubMedGoogle Scholar
  • 15 Todorova A, Georgieva B, Tournev I. et al. A large deletion and novel point mutations in the calpain 3 gene (CAPN3) in Bulgarian LGMD2A patients. Neurogenetics 2007; 8 (03) 225-229
    CrossrefPubMedGoogle Scholar
  • 16 Balci B, Aurino S, Haliloglu G. et al. Calpain-3 mutations in Turkey. Eur J Pediatr 2006; 165 (05) 293-298
    CrossrefPubMedGoogle Scholar
  • 17 Richard I, Brenguier L, Dinçer P. et al. Multiple independent molecular etiology for limb-girdle muscular dystrophy type 2A patients from various geographical origins. Am J Hum Genet 1997; 60 (05) 1128-1138
    PubMedGoogle Scholar
  • 18 Dadali EL, Shagina OA, Ryzhkova OP, Rudenskaia GE, Fedotov VP, Poliakov AV. [Clinical-genetic characteristics of limb girdle-muscular dystrophy type 2A]. Zh Nevrol Psikhiatr Im S S Korsakova 2010; 110 (04) 79-83
    PubMedGoogle Scholar
  • 19 Pogoda TV, Krakhmaleva IN, Lipatova NA, Shakhovskaya NI, Shishkin SS, Limborska SA. High incidence of 550delA mutation of CAPN3 in LGMD2 patients from Russia. Hum Mutat 2000; 15 (03) 295
    CrossrefPubMedGoogle Scholar
  • 20 Urtasun M, Sáenz A, Roudaut C. et al. Limb-girdle muscular dystrophy in Guipúzcoa (Basque Country, Spain). Brain 1998; 121 (pt. 9): 1735-1747
    CrossrefPubMedGoogle Scholar
  • 21 Renjini R, Gayathri N, Nalini A, Srinivas Bharath MM. Analysis of calpain-3 protein in muscle biopsies of different muscular dystrophies from India. Indian J Med Res 2012; 135 (06) 878-886
    PubMedGoogle Scholar
  • 22 Nalini A, Polavarapu K, Sunitha B. et al. A prospective study on the immunophenotypic characterization of limb girdle muscular dystrophies 2 in India. Neurol India 2015; 63 (04) 548-560
    CrossrefPubMedGoogle Scholar
  • 23 Khadilkar SV, Chaudhari CR, Dastur RS, Gaitonde PS, Yadav JG. Limb-girdle muscular dystrophy in the Agarwals: utility of founder mutations in CAPN3 gene. Ann Indian Acad Neurol 2016; 19 (01) 108-111
    CrossrefPubMedGoogle Scholar
  • 24 Pathak P, Sharma MC, Jha P. et al. Mutational Spectrum of CAPN3 with genotype-phenotype correlations in limb girdle muscular dystrophy type 2A/R1 (LGMD2A/LGMDR1) patients in India. J Neuromuscul Dis 2021; 8 (01) 125-136
    CrossrefPubMedGoogle Scholar
  • 25 Angelini C, Nardetto L, Borsato C. et al. The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B). Neurol Res 2010; 32 (01) 41-46
    CrossrefPubMedGoogle Scholar
  • 26 Richard I, Hogrel JY, Stockholm D. et al; Calpainopathy Study Group. Natural history of LGMD2A for delineating outcome measures in clinical trials. Ann Clin Transl Neurol 2016; 3 (04) 248-265
    CrossrefPubMedGoogle Scholar
  • 27 Fanin M, Nardetto L, Nascimbeni AC. et al. Correlations between clinical severity, genotype and muscle pathology in limb girdle muscular dystrophy type 2A. J Med Genet 2007; 44 (10) 609-614
    CrossrefPubMedGoogle Scholar
  • 28 Vanhoutte EK, Faber CG, van Nes SI. et al; PeriNomS Study Group. Modifying the Medical Research Council grading system through Rasch analyses. Brain 2012; 135 (Pt 5): 1639-1649
    CrossrefPubMedGoogle Scholar
  • 29 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424
    Google Scholar
  • 30 Chae J, Minami N, Jin Y. et al. Calpain 3 gene mutations: genetic and clinico-pathologic findings in limb-girdle muscular dystrophy. Neuromuscul Disord 2001; 11 (6,7): 547-555
    CrossrefPubMedGoogle Scholar
  • 31 Magri F, Nigro V, Angelini C. et al. The italian limb girdle muscular dystrophy registry: relative frequency, clinical features, and differential diagnosis. Muscle Nerve 2017; 55 (01) 55-68
    CrossrefPubMedGoogle Scholar
  • 32 Sáenz A, Leturcq F, Cobo AM. et al. LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain 2005; 128 (pt. 4): 732-742
    CrossrefPubMedGoogle Scholar
  • 33 Fanin M, Angelini C. Protein and genetic diagnosis of limb girdle muscular dystrophy type 2A: the yield and the pitfalls. Muscle Nerve 2015; 52 (02) 163-173
    CrossrefPubMedGoogle Scholar
  • 34 Peric S, Stevanovic J, Johnson K. et al. Phenotypic and genetic spectrum of patients with limb-girdle muscular dystrophy type 2A from Serbia. Acta Myol 2019; 38 (03) 163-171
    PubMedGoogle Scholar
  • 35 Fardeau M, Hillaire D, Mignard C. et al. Juvenile limb-girdle muscular dystrophy. Clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain 1996; 119 (pt. 1): 295-308
    CrossrefPubMedGoogle Scholar
  • 36 Fanin M, Nascimbeni AC, Angelini C. Muscle atrophy in Limb Girdle Muscular Dystrophy 2A: a morphometric and molecular study. Neuropathol Appl Neurobiol 2013; 39 (07) 762-771
    CrossrefPubMedGoogle Scholar
  • 37 Fanin M, Nascimbeni AC, Angelini C. Gender difference in limb-girdle muscular dystrophy: a muscle fiber morphometric study in 101 patients. Clin Neuropathol 2014; 33 (03) 179-185
    CrossrefPubMedGoogle Scholar
  • 38 Groen EJ, Charlton R, Barresi R. et al. Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain 2007; 130 (Pt 12): 3237-3249
    CrossrefPubMedGoogle Scholar
  • 39 Dirik E, Aydin A, Kurul S, Sahin B. Limb girdle muscular dystrophy type 2A presenting with cardiac arrest. Pediatr Neurol 2001; 24 (03) 235-237
    CrossrefPubMedGoogle Scholar
  • 40 Piluso G, Politano L, Aurino S. et al. Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypes. J Med Genet 2005; 42 (09) 686-693
    CrossrefPubMedGoogle Scholar
  • 41 de Paula F, Vainzof M, Passos-Bueno MR. et al. Clinical variability in calpainopathy: what makes the difference?. Eur J Hum Genet 2002; 10 (12) 825-832
    CrossrefPubMedGoogle Scholar